Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The aim of the present investigation is to test of the modulation obtained with denosumab as
"priming" therapy before the start of chemotherapy and as concurrent therapy in a population
of first line NPC recurrent/metastatic patients
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico del Nord-Ovest
Collaborator:
Mario Negri Institute for Pharmacological Research